Patent ID: 11919970
Assignee: JUNO THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 1:
2. The CAR of claim 1, wherein:
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 19 and 18, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 17 and 18, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 15 and 16, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 13 and 14, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 182 and 242 respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 182 and 246, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 182 and 247, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 185 and 248, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 186 and 248, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 175 and 234, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 175 and 235, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 176 and 236, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 176 and 237, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 177 and 238, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 179 and 240 respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 180 and 241, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 181 and 241, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 183 and 243 respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 183 and 244 respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 184 and 243, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 184 and 244 respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 183 and 245, respectively;
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 184 and 245, respectively; or
the VH and VL regions comprise amino acid sequences having at least 90% identity to SEQ ID NOs: 178 and 239, respectively.